Shares of MetLife, Inc. (NYSE:MET - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirteen research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $94.17.
A number of equities research analysts recently commented on the company. Piper Sandler upped their target price on MetLife from $92.00 to $94.00 and gave the company an "overweight" rating in a research report on Wednesday, April 2nd. Keefe, Bruyette & Woods dropped their price objective on shares of MetLife from $98.00 to $95.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Morgan Stanley increased their price objective on shares of MetLife from $94.00 to $99.00 and gave the stock an "overweight" rating in a research note on Monday, May 19th. Wall Street Zen downgraded shares of MetLife from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, UBS Group increased their price target on MetLife from $94.00 to $98.00 and gave the stock a "buy" rating in a research report on Wednesday, April 2nd.
View Our Latest Analysis on MET
MetLife Trading Up 1.2%
NYSE:MET opened at $80.07 on Friday. The company has a market capitalization of $53.75 billion, a P/E ratio of 13.02, a PEG ratio of 0.63 and a beta of 0.86. The company has a current ratio of 0.16, a quick ratio of 0.16 and a debt-to-equity ratio of 0.55. MetLife has a 12 month low of $65.21 and a 12 month high of $89.05. The firm has a fifty day simple moving average of $77.94 and a 200-day simple moving average of $80.17.
MetLife (NYSE:MET - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The financial services provider reported $1.96 EPS for the quarter, missing analysts' consensus estimates of $2.00 by ($0.04). The firm had revenue of $18.57 billion for the quarter, compared to analyst estimates of $18.06 billion. MetLife had a return on equity of 20.89% and a net margin of 6.08%. The business's revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.83 EPS. On average, equities research analysts anticipate that MetLife will post 9.65 earnings per share for the current year.
MetLife Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 6th were given a $0.5675 dividend. This represents a $2.27 dividend on an annualized basis and a dividend yield of 2.84%. This is a boost from MetLife's previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Tuesday, May 6th. MetLife's dividend payout ratio is 36.91%.
MetLife declared that its board has authorized a share buyback program on Wednesday, April 30th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the financial services provider to purchase up to 5.9% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.
Institutional Investors Weigh In On MetLife
A number of large investors have recently made changes to their positions in MET. Norges Bank acquired a new stake in MetLife during the fourth quarter worth about $730,716,000. Price T Rowe Associates Inc. MD grew its stake in shares of MetLife by 33.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 24,663,239 shares of the financial services provider's stock valued at $2,019,427,000 after buying an additional 6,213,923 shares during the period. Diamond Hill Capital Management Inc. acquired a new stake in shares of MetLife during the 1st quarter worth approximately $336,965,000. Nuveen LLC purchased a new stake in shares of MetLife during the 1st quarter valued at approximately $312,946,000. Finally, Clearbridge Investments LLC lifted its holdings in MetLife by 43.7% in the fourth quarter. Clearbridge Investments LLC now owns 5,663,177 shares of the financial services provider's stock valued at $463,701,000 after acquiring an additional 1,723,461 shares during the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.
MetLife Company Profile
(
Get Free ReportMetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MetLife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.
While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.